PaulMarcomMD

Oncology • Durham, NC

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Professor of Medicine, Duke University

Join to view full profile

Dr. Marcom is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marcom's full profile

Already have an account?

Office
4101 N Roxboro St
Durham, NC 27704
Phone+1 919-684-8111

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995
Duke University HospitalResidency, Internal Medicine, 1989 - 1992
Baylor College of MedicineClass of 1989

Certifications & Licensure

NC State Medical License 1991 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel Start of enrollment: 2003 Oct 01
Completed
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC Start of enrollment: 2000 Jan 01
Completed
Phase 2
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer Start of enrollment: 2008 Apr 01
Terminated
Phase 2
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Start of enrollment: 2019 Nov 21
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

42 citations
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, Benjamin J Kelly, Ana C Garrido-Castro
Nature Cancer. 2023-01-01
1 citations
Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.
Claire E P Smith, Paul K Marcom, Zahi Mitri, Naomi Y Ko
Breast Cancer Research and Treatment. 2022-11-01
15 citations
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, Timothy J Pluard, Julie R Nangia
Clinical Cancer Research. 2022-04-01

Press Mentions

Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical TeamJuly 1st, 2021
Novel Combinations Key to Advancing HR+ Breast Cancer CareDecember 27th, 2016